SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

BioAtla, Inc.
Date: May 9, 2025 · CIK: 0001826892 · Accession: 0000000000-25-004982

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-287011

Date
May 9, 2025
Author
Division of
Form
UPLOAD
Company
BioAtla, Inc.

Letter

Re: BioAtla, Inc. Registration Statement on Form S-3 Filed May 6, 2025 File No. 333-287011 Dear Jay M. Short Ph.D.:

May 9, 2025

Jay M. Short, Ph.D. Co-Founder, Chief Executive Officer and Chairman BioAtla, Inc. 11085 Torreyana Road San Diego, California, 92121

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tim Buchmiller at 202-551-3635 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Niki Fang, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 May 9, 2025

Jay M. Short, Ph.D.
Co-Founder, Chief Executive Officer and Chairman
BioAtla, Inc.
11085 Torreyana Road
San Diego, California, 92121

 Re: BioAtla, Inc.
 Registration Statement on Form S-3
 Filed May 6, 2025
 File No. 333-287011
Dear Jay M. Short Ph.D.:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Tim Buchmiller at 202-551-3635 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Niki Fang, Esq.
</TEXT>
</DOCUMENT>